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INTRODUCTION 
A DISTURBANCE in indole metabolism, particularly 5-hydroxytryptamine (5-HT) and its 
metabolites, has been proposed in various psychiatric disorders. These include schizo- 
phreniale6 and mental depression.7-g Large oral tryptophan (TP) loads given with a 
monoamine oxidase inhibitor exacerbate some of the symptoms of schizophrenics but also 
produce central nervous system effects in non-psychotic patients.lO-l3 TP has also been used 
in the treatment of depressi0n.l”l5 
In view of the fact that the primary source of brain indoles is ultimately TP, it was im- 
portant to establish that fasting plasma levels of TP and those following oral loads were 
within normal limits in psychiatric patients. Fernstrom and Wurtman16 have shown that 
rat brain 5-HT levels are related to plasma TP. They have also shown that the ratio of TP to 
other plasma neutral amino acids such as tyrosine, phenylalanine, leucine, isoleucine and 
valine regulate brain TP and hence brain 5-HT.r7 
In the present study venous blood samples from four different diagnostic groups were 
analyzed for plasma TP. The subjects were drug free chronic schizophrenics, acute schizo- 
phrenics, prisoner volunteers with personality disorders with and without depression, and 
normals consisting of staff personnel and medical students. This manuscript describes the 
changes in total plasma TP in these subjects before and after a 32 mg/kg oral TP load given 
in the morning and a standard meal containing 394.4 mg of TP and 1187 calories given in 
the evening. 
METHODS 
Schizophrenic patient population 
The chronic patients were 28 adult males, drug free for at least 6-8 months prior to the 
study. Because of discharge from the research ward for multiple reasons, smaller numbers 
were actually studied on different parameters. All patients were diagnosed as chronic 
schizophrenics independently by three to five psychiatrists and came from various state 
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hospitals in Michigan, primarily Northville State Hospital. Patients were selected on the 
basis of chronicity, failure to respond to antipsychotic drug therapy, absence of physical or 
neurological disease, and process schizophrenia. All of the patients had Bleuler’s primary 
symptoms of schizophrenia including (a) thought disorder (b) disturbance of association 
(c) autistic behavior and (d) altered affect. The patients were from 24 to 46 yr of age and were 
predominantly Caucasian. Absence of neurological and physical disease was determined on 
the basis of history, physical examination, clinical laboratory tests and EEG recordings. The 
patients were transferred from the state hospitals to the Eafayette Clinic research ward. If 
they were on medication it was abruptly withdrawn shortly after admission. Supportive 
recreational therapy including adequate exercise was initiated. Patients were given a 2300 
calorie per day diet with vitamin supplements (one Myadec/day) for at least 4 months prior 
to the study. Each patient was the subject of simultaneous psychological, physiological and 
biochemical studies carried out by other investigators at the Clinic. These studies involved 
plasmapheresis and withdrawal of blood. Patients subjected to plasmapheresis were not used 
as subjects for at least one month after this procedure. All chronic schizophrenic patients 
were additionally subdivided on the basis of presence, absence or loss of an a-2-globulin 
protein fraction as described by Frohmai? and Gottlieb et d3 These patients will be 
referred to as S-protein a helical (group A) or S-protein nonhelical (group B). A group C 
consisted of former group A patients in whom, at the time of the present study, S-protein c( 
helical was no longer measurable. The patients were classified by Dr. Frohman on the basis 
of TP uptakes done on varying occasions within a 6 month period using criteria previously 
published.2s3 
Prisoner volunteer population 
The subjects were 24 male volunteers, free of drugs for at least one month prior to study. 
They were all inmates of the State Prison of Southern Michigan. All were part of a larger 
screened pool of prisoner volunteers for Phase 1 drug studies, usually carried on in the Parke 
Davis & Company and/or the Upjohn Company facilities at this institution. Approximately 
50 such volunteers were then given an elaborate physical examination and clinical laboratory 
tests to exclude neurological and physical disease. In addition, a brief psychiatric interview 
and the self-administered MMPI was used to further assist in a psychiatric diagnosis. The 
prisoner population was characterized as predominately having personality disorders with 
definite tendencies to symptoms of depression and/or psychosis on the basis of the MMPI.18 
Two clinical psychologists were independently asked to rate the prisoners as moderately or 
mildly depressed, severely psychotic or having a character disorder. Only prisoners rated by 
both as depressed, with or without character disorder, were compared to those rated as 
normal or having a character disorder. A total of 24 prisoners was selected from a much 
larger pool of subjects. Each prisoner was given a multivitamin capsule (Myadec) every 
morning for one week prior to his participation in the study. 
Control population 
Adult males with a normal medical history and psychiatric status were selected from 
medical students and Lafayette Clinic personnel to form a control group. All fasted over- 
night prior to the morning of the test and were drug free for one to two months prior to the 
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experiment. Acetylsalicylic acid and alcoholic beverages were allowed on rare occasions but 
never during the 24-hr period immediately preceding blood withdrawal. All subjects were 
instructed to go about their usual daily activities. The control group probably had less 
exercise than the schizophrenic patients who exercised regularly. An attempt was made to 
match controls and patients for height, weight and age. The patients tended to be under- 
weight, therefore, grossly overweight controls were excluded. The control group ranged in 
age from 19 to 53 yr. 
Clinical chemistry 
Standard clinical blood and urine tests were carried out on the chronic schizophrenic 
patients and prisoner volunteers. These included hemoglobin, hematocrit, red and white 
blood cell count, serum calcium, inorganic phosphate, glucose, blood urea nitrogen, uric 
acid, cholesterol, total protein, bilirubin, alkaline phosphatase, LDH, SGOT, SGPT and 
creatinine. Urinalysis included a gross and microscopic examination, specific gravity, 
glucose and protein. 
Tryptophan source and assay 
L-tryptophan (TP) was obtained from General Biochemicals Inc. and was prepared in 2 g 
packets by the University of Michigan Hospital Pharmacy. The night before the oral TP load 
the patient or subject was weighed; 32 TP mg/kg of body wt was mixed with 2 oz apple 
sauce, 1 tablespoon sucrose and 3 drops lemon flavoring. The subjects were asked to eat the 
mixture as fast as possible. Two additional oz of apple sauce also were given to make sure all 
of the TP was ingested. Fasting venous blood samples were taken before TP administration 
at approximately 7 : 30 a.m. and further samples were taken +, 1,2,4 and 7 hr after ingestion. 
In general, all meals were withheld until after the last blood sample although occasional 
subjects obtained a 12: 00 noon lunch. Small lunches taken by mistake did not seem to affect 
the TP plasma tolerance curve. Subjects were allowed to smoke tobacco cigarettes and drink 
coffee but were discouraged from that use during the morning by substitution of lettuce 
cigarettes and decaffeinated coffee. In addition to a morning fasting sample, the schizo- 
phrenic patients were subjected to an evening fast at a later date in which a light lunch was 
served at 12 : 00 noon and no additional food given until 8 : 30 p.m. when a blood sample was 
taken. Plasma TP was determined at that time as well as several months earlier when the 
schizophrenic patients and prisoner volunteers were served a standard meal which included a 
3 oz turkey foldover with 2 oz gravy, 4 oz cauliflower, 2 oz tossed salad consisting of lettuce, 
celery, tomatoes and cucumber with 1 oz oil and 1 oz vinegar dressing, 1 slice bread, + of an 
8 in. apple pie weighing 5.5 oz, 8 oz cold milk and 8 oz Meritine (a dietary supplement). 
‘This meal contained approximately 1187 calories and 394.4 mg of TPJs 
Total plasma TP was determined by the method of Denckla and Dewey.(20) This method is 
based upon the condensation of formaldehyde with TP to form the fluorophor norharman. 
Twenty ,ul plasma samples were deproteinized with 10% trichloroacetic acid containing 
3 x 104M FeCI,. The supernatant was incubated with formaldehyde for 1 hr at 99- 
101°C. Samples and standards were read in a Farrand Mark I spectrophotofluorometer at an 
excitation and analyzing wavelength of 373 and 452 nm, respectively. TP standard was 
obtained -from Aldrich Chemical Company. All blood samples were heparinized (4 U 
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heparin/ml of blood). Samples were immediately centrifuged and the plasma removed and 
frozen at -10°C for assay, usually the next day. Frozen plasma samples were always 
assayed within one week of being drawn. 
Statistical analysis 
Computations were carried out using the Olivetti Programma 101 statistical programs.21 
These included paired and group comparison Student t-tests.22 The following TP param- 
eters were measured: fasting, peak level, largest changes in TP (ATP = peak-fasting), time 
of peak TP, 2-4 hr slope of decreasing TP, 4-7 hr slope of decreasing TP, actual measured 
area under the curve of plasma TP at O-7, O-l and 1-7 hr, and normalized area using peak 
TP as 100 per cent for O-7, O-l and l-7 hr. Half-life of plasma TP was determined on a 
semi-logarithmic graphic plot, calculating the time at which half of the peak plasma TP was 
reached extrapolating to zero time. In addition a complete’ analysis ‘of TP half life was 
also performed. 
RESULTS 
Efsts of fasting and loading on plasma TP 
Plasma TP tolerance curves were determined for normal subjects, chronic schizophrenic 
patients, and prisoner volunteers. The prisoners were divided into two groups: blood 
samples drawn at 6: 30-7:00 (group 1-12) and 7: 30-8:00 a.m. (group 13-24) after an 
overnight fast and a 32 mg/kg oral TP load. Plasma samples were taken at the times de- 
scribed earlier. The data of all groups are plotted in Fig. 1 and given in Table 1. It can be 
noted that the mean IS.E. fasting plasma TP varied from a low of 10.9 & 0.4 to a high of 
16.4 & 0.9 pg/ml among the various groups. The mean fS.E. of plasma TP for our normal 
group of 36 subjects (Table 2) was 14.2 + O-5 ,ug/ml. Denckla and Dewey20 report a mean 
fS.D. of 11.0 f 1.3 ,&ml of plasma TP taken from fingertip blood. Various other in- 
vestigators have reported normal plasma TP values varying over a wide range depending on 
the method of assay. Documenta Geigy23 lists a plasma or serum TP mean rt S.D. of 
10.8 j, 2.1 pg/ml. Adibi2g reports a mean + S.D. of 8-2 + 1.8, Perry and Hansen25 
6.3 _I 1.2, Gibbs et aLz6 20.1 + 5.3 and Bio-Science Labs2’ a mean of 14.3 ,ug/ml. Most 
investigators agree that a plasma or serum TP value of lo:20 pg/ml is within the normal 
range except for Adibiz4 and Perry and Hansen. 25 Thus, the fasting values of plasma TP 
for all of our subjects and patients fall within the broad range of normal. 
There were no significant differences in either fasting or post-TP load values between the 
mentally normal and either all schizophrenics or schizophrenic subgroups A, B and C. There 
was a significant difference in fasting plasma TP between the first 12 prisoner volunteers 
(whose samples were taken 1 hr earlier) and the last 12 volunteers (p < O*Ol), although 
the latter group had a fasting plasma TP similar to the normal controls. Comparisons 
of post-load values between the two prisoner subgroups revealed only that at 7 hr 
subgroup 1-12 had a’lower mean plasma TP level than subgroup 13-24, but this difference 
was barely significant (p = O-0548 for two-tailed t-test, p = 0.0274 for one-tailed t-test). 
The differences in the plasma TP tolerance curves between the two groups of prisoner 
volunteers were quite surprising for the prisoners originally had been randomly assigned to 
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ATP (peak minus fasting) 
rglmf 
Time of peak 
hr 
Slope, (2-4 hr) 
pg/mWu 
Slope, (4-7 hr) 
ccg/ml/hr 
Measured area (O-l hr) 
pg x hr/ml 
Normalized area (O-l) 
iug x hr/ml 
Measured area (l-7 hr) 
1ug x hr/ml 
Normalized area (l-7 hr) 
rg x hr/ml 
Measured area (O-7 hr) 
iug x hw 
Normalized area (O-7 hr) 




normal (MN) schizophrenics (CS) 
N N N 
36 14.2 rt 0.5 27 
5 87.9 f 4.6 27 
5 71.7 &- 5.3 27 
5 1.2 rt 0.2 27 
5 -17.5 f 2.3 27 
5 -6.6 & 0.7 27 
5 405 i 4.8 27 
5 48.2 f 2.4 27 
5 179.1 i 147 27 
5 219.9 & 248 27 
5 219.7 f 16.1 27 
5 268.1 & 23.7 27 
5 2.1 f 0.2 27 
16.1 f 06” 12 
91.4 & 4.6 12 
75.6 f 4.2 12 
0.9 & 0.1 12 
-146 & 1.3 12 
-6.2 & 0.4 12 
47.3 * 3.1 12 
56.9 f 2.7 12 
173.6 & 11.0 12 
208.3 & 9.7 12 
220.9 & 12.5 12 
264,8 j, 9.1 12 




14.7 & 1.0 
71.2 f 3.8* 
565 i 3*6* 
1.7 f 0.2 
-14.6 + 1.6 
-6.7 & 0.6 
26.1 & 3.4* 
43.4 & 4.6 
169.8 =!c 12.1 
293.1 + 20.7 
195.9 & 13.4 
336.5 & 20.5 
2.9 i 0.3* 
and the prisoner volunteers was that the latter tended to lie in bed much more throughout 
the experiment in contrast to the normals and schizophrenic patients who usually sat up. 
Plasma TP in acute schizophrenics and in chlorpromazine-treated chronic schizophrenics 
Values for five drug free acute schizophrenic patients are given in Fig. 2. Plasma TP in this 
group was much lower than in the normals (p < O-001). Plasma TP was measured before and 
after in a group of five chronic schizophrenics receiving chlorpromazine (CPZ), 200 mg 
t.i.d. for 1 month. These five patients had a mean f S.E. plasma TP of 14.3 f l-6 pug/ml 
while on CPZ and 14.0 f 0.7 pg/ml when drug free. Using a paired t test there was no 
significant difference in plasma levels before and after CPZ. Also when the plasma value for 
normal subjects was compared to these five, both on and off CPZ, there were no significant 
differences. 
In Fig. 2 and Table 2 are given the mean plasma TP parameters following the load. 
Compared to a larger group of normals, chronic drug free schizophrenics tended to have a 
slightly elevated plasma TP but well within the range for normal (p < O-05). After the load 
the prisoners tended to have a more flattened plasma tolerance curve which was statistically 
significant (p < O-05). The mean & S.E. time of peak TP was approximately 1.2 f O-2 hr 
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A N=s3 
FIG. 1. Mean plasma tryptophan tolerance curves following oral loading (32 mg/kg). Plasma levels of TF 
vs time are shown. Note that only the prisoner volunteers showed abnormal tolerance curves. Symbols in 
this figure are as follows: N, number of subjects, Schizophrenics A, S-protein helical, B, S-protein non- 
helical, C, S-protein variable, Prisoners 1-12 and 13-24 were two groups of which the first 12 had their 
samples drawn 1 hr earlier than the last 12. 
for the normals and peak TP for the chronic schizophrenic and prisoner volunteer groups 
was not significantly different from control. Although the normal subjects and the chronic 
schizophrenics did not differ in any other TP parameter, the prisoner volunteers (13-24) 
showed less of a TP peak, smaller ATP (peak minus fasting) and a smaller area under their 
TP tolerance curve as measured from O-l hr (p < O-05). Further, the prisoners showed a 
much longer plasma half-life which was statistically significant (p < O-05). Although the use 
of an oral TP load to measure half-life is of course subject to criticism, nevertheless, the data 
obtained indicate a mean & S.E. plasma half-life of oral TP of 2.1 f O-2 hr for normals and 
2.5 f O-1 hr for chronic schizophrenic patients. In contrast, prisoner volunteers showed a 
significantly longer mean + S.E. half-life of 2.9 & 0.3 hr (p < 0.05). 
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FIG. 2. Bar graph of mean plasma tryptophan concentration after oral loading (32 mg/kg). Four TP 
parameters are shown for various groups as indicated. Symbols in this figure are as follows: N, normal 
staff volunteers; CS, chronic schizophrenics, A, B, C as in Fig. 1; JP 13-24, Jackson prisoners. All subjects 
were run under identical conditions except AS;acute schizophrenics had only the fasting TP. Note that the 
acute schizophrenics and the prisoner volunteers differed in their TP parameters from the other groups. 
Effects of a standard meal on plasma TP in chronic schizophrenic patients and prisoner 
volunteers 
Chronic schizophrenic patients were subdivided on the basis of presence (group A) or 
absence (group B) of the cc helical S-protein, or former presence of the protein (group C). 
Patients were fasted in the afternoon and evening for S& hr in which the last meal was lunch 
at 12:00 noon. The patients had no additional food until after their blood was drawn at 
8 : 30 p.m. They were then given a regular meal. At another time the patients as well as the 
prisoner volunteers were given a standard dinner at 5 : 30 p.m. and their blood drawn at 
8 : 30 p.m. As can be seen from the data in Table 3 al1 chronic schizophrenics had a significant 
elevation in their 8 : 30 p.m. plasma determined on samples taken 3 hr postprandially com- 
pared to the 8:30 p.m. fasting plasma sample. The mean + SE. of the evening fasting 
sample was 14.4 f O-5 compared to 19.6 & O-5 pg/ml3 hr postprandial. These differences 
were also significant when the chronic schizophrenics were separated as subgroups A, B 
and C. Chronic schizophrenics in groups A and C tended to have higher plasma TP than 
those in group B (p < 0.01). Prisoner volunteers eating the standard evening meal tended to 
have less of an elevation in mean plasma TP than the schizophrenic patients. The mean f 
S.E. of 24 prisoner volunteers was 13.6 -I: O-6 compared to 19.6 i 0.5 pg/ml for the 28 
chronic schizophrenics. This difference was highly significant (p < o-001). 
TRYTOPHAN TOLERANCE CURVES 
TABLE 3. MEANPLA~M~TRYPTOPHAN FOLLOWING A STANDARD MEALIN CHRONIC SCHIZOPHRENICS AND 
PRISONER VOLUNTEERS 
Mean + SE. plasma 
Tryptophan 
Q&ml) 
Group N Evening sample fasting N Evening sample postprandial 
Chronic 
schizophrenics 22 
schizophrenics A 12 
schizophrenics B 5 
schizophrenics C 5 
Prisoner volunteers 
14.4 i 0.5$ 
14.0 f 0.q. 
15.1 f 1.q 





19.6 f 0.5 
20.X f 0.9* 
17.2 & 0.5 
20.4 & OS* 
13.6 & O-6? 
* Group comparison t-test p < 0.01 compared to chronic schiiophrenics Group B. 
t Group comparison t-test p < 0.001 compared to all chronic schizophrenics. 
z Paired comparison t-test p < 0.01 for those patients common to both fasting and postprandial states, 
Plasma TP in nondepressed vs depressed prisoner volunteers 
Prisoner volunteers were separated into two groups on the basis of their MMPI scores as 
not depressed vs depressed. Both groups also had personality disorder characteristics as 
would be expected of prisoners. As illustrated in Fig. 3 and Table 4, there were significant 
differences in the prisoner volunteers on various TP parameters. The nondepressed prisoners 
tended to have slightly higher mean Irt S.E. plasma TP in response to a standard meal as well 




FIG. 3. Mean plasma tryptophan levels in non-depressed vs depressed prisoners. ND, Non-depressed, 
D, depressed prisoners on the basis of their MMPI scores. Both groups showed personality disorders but no 
psychotic tendencies. Note that the depressed prisoners differ significantly (p < 0.05) on two of the four 
TP parameters shown. 
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ATP (peak minus fasting) 
&ml 
Time of peak 
hr 
Slope (2-4 hr) 
fig/ml/hr 
Slope (4-7 hr) 
/&Wr 
Measured area (O-l hr) 
i% x hrid 
Normalized area (O-l hr) 
pg x wml 
Measured area (1-7 hr) 
peg x hr/ml 
Normalized area (1-7 hr) 
iug x Wml 
Measured area (O-7 hr) 
pg x hr/mI 
Normalized area (O-7 hr) 
rug x hr/d 
Plasma half-life 
hr 
*As in Table 1. 
14.7 f 0.9 12.2 * 0.7* 
13.9 * 1.0 11.1 rt 0.6” 
67.1 + 4.2 59.2 & 3.3 
53.2 & 3.7 48.1 f 3.5 
1.9 & 0.1 1.5 5 0.2 
-13.6 j, 2.3 -12.8 & 0.7 
-7.4 & 0.4 -4.9 f 0.8” 
21.8 & 3.3 28.2 f 3.7 
39.7 & 5.0 51.8 & 40 
167.7 f 13.8 138.0 & 8.4 
314.6 & 30.3 260.6 f 13.4 
1895 & 141 166.2 f 10.4 
3544 & 29.4 312.3 + 11.8 
3.1 & 0.4 2.3 h 0.2t 
P Significant at 0.05 level, one-tailed group comparison t-test. 
as in the morning fasting state (p < 0.05). Eight nondepressed prisoner volunteers had a 
mean & S.E. plasma TP following the standard meal of 14.7 f 0.9 compared to seven 
depressed prisoner volunteers who had 12.2 & O-7 pg/ml (p < O-05). The same situation 
was true for the morning fasting state. The nondepressed prisoners had a fasting plasma TP 
of 13.9 & 1-O compared to the depressed prisoners who had a TP level of 11.1 & O-6 pg/ml. 
Numbers of prisoners from both the 1-12 vs 13-24 groups were distributed in these two 
groups such that the difference in a.m. fasting TP between groups was unrelated to a 1 hr 
difference in blood drawing time. There were no significant differences in peak TP, ATP, 
time of peak TP or the 2-4 hr slope of plasma TP in response to the oral TP load. However, 
the depressed prisoners had a significantly different TP slope from 4-7 hr. All other param- 
eters were similar except that mean plasma half-life tended to be shorter for the depressed 
prisoners. 
DISCUSSION 
There have been many quantitative studies on metabolites of TP in blood and urine and its 
regulation by vitamin Be and steroid hormones. 28 Various investigators have used TP load 
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tests in studying epilepsy,2g scleroderma,30 and mongolism.31 One of the most impressive 
studies measuring plasma TP tolerance curves after an oral TP load has been that of Yarbro 
and Andersor? in phenylketonuric patients. These investigators showed a marked dis- 
turbance in the absorption peak and disappearance of plasma TP in phenylketonurics 
compared to normal children. This is presumably because the high phenylalanine levels of 
phenylketonurics compete with TP for the aromatic amino acid transport system. 
Price and his associates33 have reviewed some evidence for a functional disturbance in the 
tryptophan-niacin pathway in chronic schizophrenic patients. Kopin34 found that the 
excretion of 5-hydroxyindoleacetic acid was completely normal in chronic schizophrenic 
patients under basal and oral TP loading conditions. Szafranek3” reported a difference in 
plasma TP in chronic schizophrenic patients when they were on phenothiazine medication. 
Plasma TP appeared to be elevated using a calorimetric analysis. Inasmuch as it is known 
that psychotropic drugs alter most free amino acids in the brain,36 it seemed crucial to 
measure plasma TP under non-drug conditions. However, it should be noted that in the 
present study five chronic schizophrenics showed no difference in fasting plasma TP before 
or after approximately one month of 600 mg of daily chlorpromazine. 
In general, chronic schizophrenic patients free of drugs did not differ significantly from 
controls in either mean fasting plasma TP or after an oral load. A subdivision of chronic 
schizophrenic patients with and without a helical S-protein of Frohman and Gottlieb2s3 did 
not reveal any significant differences except that those with a helical S-protein tended to have 
a higher plasma TP in response to the standard dinner. However, their TP tolerance curves 
were normal. We have no explanation for this discrepancy. Obviously there are marked 
differences between an amino acid load and a complete meal including the time of the day, 
and differential rates of breakdown, absorption, and utilization of food, etc. A barely 
significant (p -C 0.05) increase in mean plasma fasting TP was observed in all of the chronic 
schizophrenic patients compared to all normals. In contrast, the acute schizophrenic 
patients showed a lower mean plasma TP than the normals or chronic patients @ < O*OOl). 
Although this difference was statistically significant, plasma TP for all patient groups was 
within the normal range. 
Recently, Manowitz and Gilmour et a1.37*38 reported that acute schizophrenic patients 
have low plasma TP and normal phenylalanine and tyrosine levels. Because plasma TP was 
selectively reduced these investigators concluded this could not be due to an inadequate diet 
although a control for starvation was not included. Our findings in acute schizophrenic 
patients confirm that plasma TP is reduced. The fact that hospitalization of acute patients 
causes plasma TP to return to normal can be interpreted either as due to diet or reduced 
stress. 
It has been known for some time that most plasma TP is bound to plasma proteins.39 
More recently Knott and Curzon40 and Gessa et aL41 have reexamined this phenomenon 
in relation to brain TP and 5-HT. Brain TP is highly correlated with the much smaller ultra- 
filterable fraction of free plasma amino acids. Hence an examination of free vs bound plasma 
or serum TP in mental disease is of great interest. We are now doing this in chronic schizo- 
phrenic patients. 42 As has been pointed out by Fernstrom and Wurtman,16 brain 5-HT 
content in the rat is dependent on plasma TP under normal fasting or circadian rhythm 
conditions. While brain 5-HT content increases with a relative increase in plasma TP as can 
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occur with a load, after a standard meal brain 5-HT is regulated by the ratio of various 
plasma neutral amino acids to TP .17 This finding is to be expected in view of the fact that 
various amino acids compete for the same transport system as TP. It is also well known that 
there is a variation in plasma TP both in the rat16 and human43*44 depending upon the 
time of the day. Young et al. 45 have also studied the effects of TP intake, spacing of meals, 
and diurnal fluctuations in plasma TP in man. Weller et al .46 have reported upon changes in 
fasting of postprandial amino acids of men fed an adequate or protein free diet. 
Our own studies comparing prisoner volunteers 1-12 and 13-24 to controls showed that 
administering the load 1 hr earlier (6 : 30-7 : 00 a.m. for 1-12 compared to 7 : 30-8 : 00 a.m. for 
13-24) resulted in a highly significant difference in mean fasting and post-load plasma TP. 
Thus, time of the day as well as diet appear to be critical in the measurement of plasma TP. 
Depressed prisoners showed a significant decrease in fasting plasma TP and decreased 
plasma TP response to a standard meal. The 4-7 hr slope of TP disappearance after load 
was less in the depressed patients, although a reason for this is not obvious at present. The 
decreased plasma TP may be related to alterations in growth hormone and corticosteroids 
that have been demonstrated in depression. Lapin and Oxenkrug4’ have postulated that 
depressed patients may have a shunting of TP toward the kynurenine pathway due to an 
increase in liver tryptophan oxygenase activity induced by corticosteroids which are elevated 
in depression.48 On the other hand the response of growth hormone to L-Dopa is reduced 
in depressed patients. 4s Growth hormone reduces corticosteroid stimulation of tryptophan 
oxygenase.50 Both of these endocrine alternations in depression would tend to facilitate TP 
removal from the plasma. While such a hypothesis might account for the decrease in fasting 
levels of plasma TP in the depressed prisoners in this study, this does not seem to be a 
universal finding. Coppens has not observed a significant difference in mean plasma total 
TP in depressed vs nondepressed patients. Our finding of a decreased slope of TP disap- 
pearance in the depressed prisoner volunteers is paradoxical since this would indicate a 
generally flatter TP tolerance curve in depressed patients. Obviously, this finding must be 
repeated in other depressed people since a prisoner population has a most complex psy- 
chiatric and environmental status. 
An important difference between the prisoner volunteers and the other patients studied 
was the fact that the prisoner study was carried out on a hospital ward while the patients and 
normals were studied in a laboratory environment. This allowed the prisoners to lie in bed 
and many of them slept through much of the study even though they were free to walk 
around. The normal volunteers and the chronic schizophrenics usually sat up and went 
about their normal activities without the opportunity of lying down. This might account for 
some of the differences observed. 
There were remarkably few side effects following the 32 mg/kg TP load. Several of the 
chronic schizophrenics showed symptoms resembling hypoglycemia or hypotension although 
no significant change in blood pressure was observed. In spite of a lo-fold elevation in 
plasma TP, no psychic or mental changes were observed such as have been reported with 
much larger doses of TP in normal volunteers or in patients given TP plus a monoamine 
oxidase inhibitor.lO-l2 
In the present study we had a great deal of difficulty preventing subjects or patients from 
smoking tobacco cigarettes and drinking coffee. This was overcome in part by allowing the 
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subjects to smoke tobacco-free cigarettes and drink decaffeinated coffee. Although Brown et 
~1.~~ have shown that tobacco smoking has no significant effect on the excretion of TP 
metabolites in man, the role of coffee drinking on plasma TP has yet to be studied. Dietary 
deprivations decrease concentrations of some essential serum amino acids in man(4s) 
although much more needs to be known for TP. The prisoner volunteers in general had a 
much poorer diet compared to the high protein meals available to the chronic schizophrenic 
patients. Thus, it may be that some of the changes observed in mean fasting TP might be 
explained on a nutritional basis. 
What is dramatically clear is that there are no marked differences in the way TP is 
absorbed or handled in the blood stream of chronic schizophrenic patients. TheJinding of a 
d@erence in the plasma TP tolerance curve of depressed us nondepressed prisoners must be 
regarded as extremely preliminary since the entire prisoner group showed abnormalities. 
Additional studies using oral TP loads in acute schizophrenics and depressed patients are 
clearly warranted. However, the role of nutritional and endocrine abnormalities will have to 
be carefully ascertained and controlled. 
SUMMARY 
Plasma TP was determined fluorometrically in four groups of males: (1) normal controls 
(2) chronic schizophrenics (3) acute schizophrenics and (4) prison volunteers with personality 
disorders with and without symptoms of depression. To control for circadian rhythm all 
subjects were fasted overnight or in the afternoon and evening prior to withdrawal of venous 
blood. Fasting a.m. orp.m. plasma TP was within the range of normalfor allgroups. However, 
the acute schizophrenics and prison volunteers had lower plasma TP than the normal 
controls and chronic schizophrenics (p < 0.01). Plasma TP was determined before an 
8 : 00 a.m. TP load and at 8, 1,2,4 and 7 hr after ingestion. A plasma tolerance curve was 
obtained with a peak at l-2 hr which returned almost to normal at 7 hr. Various TP param- 
eters were measured including fasting, peak, maximal change in TP, time of peak, slope 2-4 
and 4-7 hr, measured and normalized areas under the plasma tolerance curve, and plasma 
half-life. Almost no significant differences were found between normal controls and the 
chronic schizophrenics. Although all prison volunteers showed a markedly different TP 
tolerance curve from either the normal controls or chronic schizophrenics, depressed 
prisoners had a significantly lower and flatter curve. It appears that TP is well absorbed 
from the gastrointestinal tract and its plasma half-life is normal in chronic schizophrenics. 
Further studies in acute schizophrenics and depressed patients are indicated. 
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